Drug Trial Radar · NCT06790862
A Trial of SHR0302Base in Patients With Vitiligo
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
155
Actual
Start
Feb 13, 2025
Primary completion
Mar 3, 2026
Study completion Apr 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.
Conditions
- Vitiligo
Interventions
SHR0302Base gelDrug
SHR0302Base gel.
SHR0302Base gel placeboDrug
SHR0302Base gel placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who achieved at least a 50% improvement from baseline in the facial-neck vitiligo area score (F-VASI 50 response).Time frame: At week 24.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital affiliated to Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.